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Abstract The AMP-activated protein kinase (AMPK) in rat
skeletal and cardiac muscle is activated by vigorous exercise and
ischaemic stress. Under these conditions AMPK phosphorylates
and inhibits acetyl-coenzyme A carboxylase causing increased
oxidation of fatty acids. Here we show that AMPK co-
immunoprecipitates with cardiac endothelial NO synthase
(eNOS) and phosphorylates Ser-1177 in the presence of Ca2+-
calmodulin (CaM) to activate eNOS both in vitro and during
ischaemia in rat hearts. In the absence of Ca2+-calmodulin,
AMPK also phosphorylates eNOS at Thr-495 in the CaM-
binding sequence, resulting in inhibition of eNOS activity but
Thr-495 phosphorylation is unchanged during ischaemia. Phos-
phorylation of eNOS by the AMPK in endothelial cells and
myocytes provides a further regulatory link between metabolic
stress and cardiovascular function.
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1. Introduction
The AMP-activated protein kinase (AMPK) isoforms K1
and K2 consist of a catalytic K subunit [1,2] together with L
and Q non-catalytic subunits [3^5]. AMPK is related to the
Saccharomyces cerevisiae SNF1 protein kinase required for
expression of glucose-repressed genes during nutritional stress
[6]. AMPK phosphorylates a range of metabolic enzymes [7]
and has recently been implicated in an increasing number of
physiological functions including glucose transport [8] and
regulation of transcription [9] (reviewed in [10]). The
AMPK-K2 isoform is present in capillary endothelial cells in
cardiac and skeletal muscle and the AMPK-K1 isoforms oc-
curs in cardiac myocytes and vessels (results not shown). The
presence of AMPK in endothelial cells prompted us to test the
hypothesis that endothelial NO synthase (eNOS) may be an
AMPK substrate using bacterially expressed eNOS.
2. Materials and methods
2.1. AMPK-K1 puri¢cation and assay
The AMPK was puri¢ed from rat liver and assayed using the pro-
cedures previously reported [11]. Immunoblotting of the isoforms of
the AMPK was done with antibodies raised against the following
peptides: K2(490^516) or K1(373^390).
2.2. Phosphorylation site sequencing
Phosphopeptides isolated from in-gel tryptic digests as described
[12] were separated by reversed phase chromatography (Pharmacia
SMART system). More than 98% of the radioactivity was recovered
from the gel. The separated peptides were analysed using a linear
Voyager DE (PerSeptive Biosystems) MALDI-TOF instrument in de-
layed extraction mode. Location of the phosphorylation site in pep-
tide ‘TQXFSLQER’ was identi¢ed by [32P]phosphate release sequenc-
ing [12] (Fig. 1).
2.3. NO synthase assay
The eNOS activity was determined by measuring L-[3H]citrulline
production [13]. The recombinant eNOS was co-expressed with cal-
modulin (CaM) [14]. In the absence of added EGTA, CaM depend-
ence was observed at 0^100 nM added CaM. In order to investigate
the changes in NOS activity with phosphorylation, in the absence and
presence of Ca2-CaM preincubation, EGTA bu¡ering was used to
achieve CaM dose-response curves in the range 0^1 WM. Routinely, 7^
15 WM EGTA was added to make eNOS activity dependent upon
added CaM. Where Ca2-CaM was used in the phosphorylation re-
action, prior to the eNOS assay, the samples were either diluted so
that the added Ca2-CaM was negligible or the indicated concentra-
tions represent total ¢nal concentrations of added Ca2-CaM. Car-
diac eNOS was partially puri¢ed from 20 rat hearts homogenised in
80 ml of ice-cold bu¡er A (50 mM Tris-HCl bu¡er, pH 7.5 containing
1 mM EDTA, 1 mM EGTA, 1 mM DTT, 50 mM NaF, 5 mM Na
pyrophosphate, 10 Wg/ml trypsin inhibitor, 2 Wg/ml aprotinin, 1 mM
benzamidine, 1 mM PMSF, 10% glycerol and 1% Triton X-100). The
homogenate was put on ice for 30 min and centrifuged at 16 000Ug
for 30 min. The supernatant was incubated with 2 ml of 2P,5P-ADP
Sepharose [15]. After 1 h incubation, the suspension was poured into
a fritted column, washed with 20 ml of bu¡er A, 20 ml of bu¡er A
with 0.5 M NaCl, and then with 20 ml of bu¡er B (50 mM Tris-HCl,
pH 7.5, 1 mM DTT, 10% glycerol, 0.1% Triton X-100). eNOS was
eluted with bu¡er B containing 2 mM NADPH then subjected to
centrifugal ultra¢ltration (Ultrafree-MC, Millipore) to remove
NADPH. The isolated eNOS contained only a faint trace of nNOSW
detected by immunoblotting using an nNOS antibody that recognises
nNOSW from skeletal muscle [16].
2.4. Antiphosphopeptide-speci¢c antibodies
Rabbit polyclonal antibodies raised against phosphopeptides based
on the amino acid sequence of human eNOS RIRTQSpFSLQER (S-
1177) and GITRKKTpFKEVANCV (T-495) were puri¢ed using the
corresponding phosphopeptide a⁄nity columns after pre-clearing with
dephosphopeptide a⁄nity columns. The speci¢city of the puri¢ed
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antibodies was evaluated by both enzyme immunoassay and immuno-
blotting, showing that they did not recognise dephospho-eNOS.
3. Results and discussion
Recombinant eNOS [17] was readily phosphorylated in the
presence of AMPK and [Q-32P]ATP but not in the absence of
AMPK. AMPK-K1 (Fig. 1, top left panel) and AMPK-K2
(not shown) isoforms phosphorylate eNOS. Following tryptic
digestion of the phosphorylated recombinant eNOS revealed
four phosphopeptides generated from three separate sites (Fig.
1, bottom panel, A, AP, B, C) on the phosphopeptide map.
Identi¢cation of phosphorylation sites by mass spectrometry
and Edman sequencing [18] revealed Ser-1177 was the most
prominent phosphorylation site (Fig. 1, bottom panel, A
(TQSFSLQER), AP (IRTQSFSLQER)). A second site, Thr-
495, was phosphorylated in the absence of Ca2-CaM or
when EGTA was present (Fig. 1, bottom panel, B (KKTFKE-
VANAVK)). This residue is located in the CaM-binding se-
quence, TRKKT495FKEVANAVKISASLM, between the ox-
idase and reductase domains of eNOS [19]. Ser-101 was
identi¢ed as a minor site with low stoichiometry (Fig. 1, bot-
tom panel, C, CLGS101LVFPR). Synthetic peptides corre-
sponding to Thr-495 and Ser-1177 phosphorylation sites
were readily phosphorylated by AMPK: GTGIT-
RKKT495FKEVANAVK, Km 39 þ 10 WM and Vmax 6.7 þ 0.6
Wmol/min/mg; RIRTQS1177FSLQERQLRG, Km 54 þ 6 WM
and Vmax 5.8 þ 0.3 Wmol/min/mg. The well characterised
AMPK peptide substrate, SAMS is phosphorylated with
a Km of 33 þ 3 WM and Vmax of 8.1 þ 1.5 Wmol/min/mg
[20,21]. Previous studies on the speci¢city of AMPK with
synthetic peptides supported the concept that hydrophobic
residues at the P35 and the P+4 position were important
[21]. While the Thr-495 site conforms to this arrangement,
the Ser-1177 site has hydrophobic residues at P34 and P+3
and yet it is a good substrate, suggesting that the AMPK may
target a greater diversity of sequences than was previously
recognised.
Unlike native eNOS, bacterial expressed enzyme is not
post-translationally myristoylated or palmitoylated and for
this reason it was important to test puri¢ed rat heart eNOS
as a substrate for the AMPK. Phosphorylation of rat heart
eNOS with AMPK also resulted in Thr-495 and Ser-1177
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Fig. 1. Phosphorylation of recombinant eNOS with AMPK. Upper
left panel: Recombinant eNOS (1 WM), co-expressed with CaM [14],
was incubated with rat liver AMPK K1 (10 nM) and [Q-32P]ATP for
20 min at 20‡C. Coomassie-stained SDS-PAGE (lane 1) and autora-
diograph (lane 2) are shown. Upper right panel: [32P]tryptic phos-
phopeptide map of eNOS from in-gel tryptic digests as previously
described [12] with o marking the origin. Lower table: mass analysis
of phosphopeptides; pc denotes pyridylethyl cysteine, * denotes cal-
culated mass of mono-phosphorylated peptide. Location of the
phosphorylation site in peptide ‘TQXFSLQER’ was identi¢ed by
[32P]phosphate release sequencing in the third cycle [12].
Fig. 2. E¡ect of phosphorylation of rat heart eNOS by AMPK with
or without added Ca2-CaM. A: Rat heart eNOS (30 nM) puri¢ed
by 2P,5P-ADP-Sepharose a⁄nity chromatography was phosphoryl-
ated by AMPK (1.3 nM) (20 min at 20‡C) in the presence of 0.8
WM CaM/3.2 WM Ca2 (b), in the absence of Ca2-CaM (S) and
without AMPK (E). After phosphorylation, the samples were di-
luted, and eNOS activity was measured. B: Phosphopeptide maps
of rat heart eNOS phosphorylated with and without added Ca2-
CaM. The phosphorylation stoichiometry ranged from 0.3 to 0.5
mol/mol under these conditions. C: Immunoblotting of phosphory-
lated eNOS, eNOS phosphorylation as described in A. Polyclonal
antibodies raised against synthetic phosphopeptides to the eNOS
phosphorylations sites RIRTQSpFSLQER (labeled S-1177) and
GITRKKTpFKEVANCV (labeled T-495) were used to detect phos-
phorylation of eNOS by immunoblotting.
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being phosphorylated with Ser-1177 phosphorylation more
prominent in the presence of Ca2-CaM (Fig. 2A). Phospho-
rylation of rat heart eNOS Ser-1177 was associated with acti-
vation of eNOS. Phosphorylation shifted the dose-response
curve for CaM to the left (Fig. 2A). Activation of recombi-
nant eNOS or bovine aortic endothelial cell eNOS incubated
in the presence of Ca2-CaM was also observed with Ser-1177
phosphorylation (not shown). In order to ensure that the
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Fig. 3. E¡ect of ischaemia on the AMPK-K1 and K2 activities and eNOS. A: Rat heart homogenates were immunoprecipitated with either an
anti-mouse immunoglobulin (IgG, negative control) or an anti-eNOS monoclonal antibody (ECNOS, Trans.Lab.). Immunoprecipitates were im-
munoblotted for eNOS and AMPK-K1 and K2. An eNOS and AMPK positive controls are shown (Control). B: Langendorf isolated perfused
rat hearts were subjected to ischaemia as described previously [23]. The AMPK-K1 and K2 were immunoprecipitated and assayed using the
SAMS peptide substrate. Results shown are means þ S.E.M. for n = 5. C: The results show eNOS activities with full CaM-dose responses for a
representative experiment. Ischaemia time point 0 min (E), 1 min (8), 10 min (b) and 20 min (O). D, E: E¡ect of ischaemia on eNOS phos-
phorylation. Rat heart eNOS was isolated from homogenates run on SDS-PAGE and immunoblotted. Perfused hearts followed by 0 min (lane
1) or 10 min (lane 2) ischaemia as described above. Anti-eNOS antibody (eNOS-6c6, Zymed, eNOS (1^35)) and puri¢ed polyclonal antiphos-
phopeptide antibodies for Ser-1177 and Thr-495 were used. Quantitative densitometric data shown, mean þ S.E.M., n = 6 experiments.
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presence of CaM in the phosphorylation reaction did not
in£uence the subsequent eNOS assay, EGTA bu¡ering was
used to lower Ca2 to ensure that the eNOS activity was
dependent on added CaM to its assay. By inclusion of
EGTA the eNOS CaM dependence was shifted from the
low nM range to the high nM range. In the absence of added
AMPK pre-incubation with or without CaM did not alter the
activity of eNOS assayed using EGTA bu¡ering. Using phos-
phopeptide mapping we found that activation of eNOS corre-
lated with phosphorylation of Ser-1177 and not Thr-495 (Fig.
2B). Phosphorylation without added Ca2-CaM enhanced
Thr-495 phosphorylation, suppressed Ser-1177 phosphoryla-
tion, and reduced eNOS activity (Fig. 2A,B). Phosphopep-
tide-speci¢c antibodies to these sites were used in immuno-
blots following phosphorylation of rat heart eNOS (Fig. 2C)
and these gave similar results to the phosphopeptide maps.
Isolated rat heart eNOS had detectable phospho-Thr-495
and -Ser-1177. Previously it has been shown that phospho-
rylation of synthetic peptides containing Thr-495 by protein
kinase C inhibits their CaM binding [22] and the inhibition of
eNOS following phosphorylation at this site is consistent with
reducing CaM binding.
In rat heart extracts both the K1 and K2 AMPK isoforms
co-immunoprecipitated with eNOS (Fig. 3A) but not with a
control antibody showing that eNOS in both capillary endo-
thelial cells and myocytes [13] is associated with the AMPK,
supporting the idea that the AMPK and eNOS co-localise in
heart. AMPK is a multisubstrate enzyme and we expect only a
portion of the enzyme to be associated with eNOS. Previously
it was reported that cardiac AMPK is activated during ischae-
mia [23], and we ¢nd both K1 and K2 isoforms activated 2-
and 3-fold respectively up to 10 min then decline (Fig. 3B),
indicating that AMPK derived from both capillary endothelial
cells and cardiac myocytes is activated. During ischaemia
there was an approximately 2-fold increase in eNOS activity
by 10 min and a shift in the CaM dose response (Fig. 3C)
mimicking the e¡ect of eNOS phosphorylation by AMPK in
vitro. Using the antiphosphopeptide antibodies to Ser-1177
and Thr-495 phosphorylation sites we observed that phos-
phorylation of Ser-1177 was increased approximately 3-fold
with ischaemia (Fig. 3D,E) but there was no detectable change
in the Thr-495 phosphorylation under these conditions. These
results support the concept that activation of the AMPK dur-
ing ischaemia directly correlates with the activation of eNOS.
The presence of nNOSW has been reported for heart but we
could detect only trace nNOSW immunoreactivity in NOS pu-
ri¢ed from hearts using ADP-Sepharose chromatography. For
this reason we do not consider that nNOSW is contributing to
the increased activity observed with ischaemia.
Our results support the concept that eNOS is autoinhibited
by its COOH-terminal tail, and phosphorylation at Ser-1177
reverses this inhibition to further activate the enzyme in con-
cert with Ca2-CaM. There is a high level of similarity be-
tween eNOS and nNOS in their COOH-terminal tails whereas
iNOS is distinct (Fig. 4). In contrast to eNOS and nNOS, the
CaM-binding properties of iNOS are characterised by a low
Ca2-dependence. By using chimeras of iNOS and nNOS it
was found that the COOH terminal domain is important in
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Fig. 4. Comparison of NO synthase phosphorylation site sequences. Schematic model of NO synthase showing sequences from the CaM-bind-
ing region (around Thr-495 phosphorylation site in eNOS) and for the COOH-terminal tails (around Ser-1177 phosphorylation site in eNOS).
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conferring the lower Ca2-dependence of iNOS [24] and it
may be consistent with iNOS not having the same form of
autoinhibition by its COOH terminal tail. Further, both iNOS
and nNOS lack a phosphorylatable residue equivalent to Thr-
495 and therefore would not have their CaM binding proper-
ties altered by phosphorylation in this region.
Previous studies have shown that eNOS may be phospho-
rylated both in vitro and in vivo but the function and precise
sites of phosphorylation have not been fully characterised
(reviewed in [25]). Thus far eNOS is the only example of an
enzyme activated by AMPK. Phosphorylation alters eNOS
activity in concert with the Ca2-CaM regulation by inhibit-
ing activity with low calcium and increasing it with high cal-
cium. During ischaemia only the Ser-1177 site phosphoryla-
tion is increased and not the Thr-495 site. The mammalian
AMPK provides an interesting means of integrating metabolic
stress signals within endothelial cells and myocytes to control
eNOS and thereby potentially modulating the local circula-
tory system to improve nutrient supply and suppress mechan-
ical activity of the muscle.
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